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Abstract 
Purpose: Chronic kidney disease (CKD) is a common complication among patients with diabetes mellitus; however, noncompliance with 
the recommended annual screening is common. Increased screening among high-risk patients is important to identify the early stages 
CKD, potentially resulting in earlier treatment, slower progression, fewer complications, and decreased healthcare expenditures. 
Motivational interviewing (MI) has previously been shown to be effective for various behaviors, such as smoking cessation and 
cholesterol level control. The objective of this study is to evaluate the effectiveness of pharmacist-delivered MI compared to typical 
education (TE) methods in increasing CKD screening and subsequent angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II 
receptor blocker (ARB) initiation in high-risk patient populations. 
Methods: Pharmacists screened diabetic patients within their chronic disease management clinic to identify patients that are at high-
risk for CKD, indicated by a score of 4 or greater on the validated SCORED screening tool. High-risk patients were randomized to one of 
four groups to receive either one or two face-to-face education sessions from a pharmacist or student pharmacist using either MI or 
TE methods. Patients were then given the option to have their urine tested with a dipstick to detect albumin and creatinine, provided 
at no cost. The primary outcome was to determine the rate of urinary albumin testing, and the secondary outcome was to determine 
the rate of ACE-I or ARB initiation in patients found to have albuminuria. 
Results: There were no significant differences in the rates of urinary albumin screening (87% in TE vs. 100% in MI, P = 0.4828) or 
subsequent ACE-I/ARB initiation (100% in TE and 50% in MI, P = 1.000) between education groups. Of the high-risk patients who 
underwent urinary albumin screening, 54% (n=15) were found to have proteinuria 
Conclusions: While it appears that MI does not impact patient acceptance rates of microalbuminuria screening and ACE-I/ARB 
initiation, this study demonstrates the feasibility of pharmacist-delivered microalbuminuria screening in patients at high-risk for CKD 
in the outpatient setting. 
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Introduction 
Diabetic nephropathy is the primary cause of renal disease in 
the United States, occurring in 36% of patients with diabetes 
mellitus.1,2 Current guidelines recommend assessment of 
urinary albumin and estimated glomerular filtration rate at 
least annually in patients with type 1 diabetes with duration of 
5 or more years, type 2 diabetes, or those with comorbid 
hypertension.3 However, previous studies indicate that a 
majority of patients with diabetes mellitus are not routinely 
screened for microalbuminuria, particularly those with low 
health literacy and socioeconomic status.4,5 Additional risk 
factors for the development of diabetic nephropathy include 
uncontrolled blood pressure, dyslipidemia, smoking, dietary 
protein intake, and family history.1 One study demonstrated 
that a scoring system, Screening for Occult Renal Disease 
(SCORED), weighted toward these common variables 
associated with CKD, may be a useful tool in the identification 
of individuals with a high likelihood of kidney disease.6 
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According to the United States Renal Data System, total 
Medicare spending on both chronic kidney disease (CKD) and 
end-stage renal disease (ESRD) is over $114 billion annually.2 
Increased screening among high-risk patients is necessary to 
identify the early stages of CKD, potentially resulting in earlier 
treatment, slower progression, fewer complications, and 
decreased healthcare expenditures for the disease.  
Pharmacists are well-positioned to assume a more active role 
in screening for CKD in the primary care setting to improve 
patient care, particularly in these high-risk patient populations. 
Studies have investigated pharmacist screening for other major 
diseases such as osteoporosis, cardiovascular disease, 
depression, hypercholesterolemia, and peripheral vascular 
disease, indicating the feasibility of pharmacist-delivered 
screening services.7 
One method used by pharmacists to encourage adherence 
amongst their patients is motivational interviewing (MI). MI is a 
patient-centered, directive approach for enhancing motivation 
to change by assessing a patient’s knowledge and exploring, as 
well as resolving ambivalence.8 MI has previously been shown 
to be effective in smoking cessation, human immunodeficiency 
virus (HIV) risk reduction, weight loss, decreased alcohol use, 
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and cholesterol level control.9,10,11 Miller, et al. concluded that 
MI also shows promise for increasing patient willingness to 
undergo health screenings.12 
Currently, there is no published literature evaluating the 
effectiveness of MI in increasing patient follow-ups with CKD 
screening. Given the opportunities for pharmacist-delivered 
screening services and the potential for MI to increase a 
patient’s willingness to undergo health screenings, this study 
sought to determine the impact of pharmacist-delivered MI 
versus typical education (TE) methods on the rates of 
microalbuminuria screening in diabetic patients of low 
socioeconomic status at high-risk for CKD. 
Methods 
This was a prospective, randomized, community intervention 
pilot study conducted at the Community Health Center (CHC) of 
West Palm Beach. The research protocol was approved by the 
Palm Beach Atlantic University Institutional Review Board. 
Pharmacists at the CHC provide chronic disease state 
management services for diabetes mellitus, hypertension, and 
dyslipidemia through a collaborative practice agreement for 
patients of low socioeconomic status who are uninsured and do 
not have access to healthcare services.  
From October 2018 to February 2019, pharmacists and student 
pharmacists screened patients with diabetes within their clinic 
to identify patients at high-risk for CKD, indicated by a score of 
4 or greater on the validated SCORED tool (see Figure 1).5 Per 
Bang, et al., patients with a score of 4 or greater on the SCORED 
tool have a 20% chance of having CKD.6 Patients that scored less 
than 4 on the SCORED tool and patients with a diagnosis of CKD 
or ESRD, per patient-report or as documented in the electronic 
medical record, were excluded from the study. High-risk 
patients were randomized to one of four groups to receive face-
to-face education sessions from a pharmacist or student 
pharmacist: 1) one TE session, 2) two TE sessions, 3) one MI 
session, or 4) two MI sessions. The TE or MI session was 
incorporated into the regular clinic visit and typically took 2 to 
5 minutes to complete. Scripts followed during the TE and MI 
education sessions are provided in Appendix A. After education 
was provided, patients were given the option to undergo urine 
testing with a urine dipstick to detect albumin/creatinine ratio, 
which was provided at no cost to the patients. An 
albumin/creatinine ratio > 30 mg/dL was considered positive. 
The urine dipstick used had a sensitivity of 96.5% and specificity 
of 98.3% for the microalbumin test.  
The primary outcome of this study was the rate of urinary 
albumin testing. The secondary outcome was the rate of 
angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin 
II receptor blocker (ARB) initiation, which have been found to 
reduce the progression of CKD, in patients found to have 
albuminuria who were not currently prescribed either an ACE-I 
or ARB. Medication adherence was assessed in patients with 
albuminuria who were currently prescribed either an ACE-I or 
ARB by calling the patients pharmacy to review refill history or 
with pill counts for patients who obtained their ACE-I/ARB from 
clinic supplies.  
Statistical analysis was done using Microsoft Excel®. Differences 
in the primary and secondary outcomes were assessed for 
significance using Fisher’s exact test. To achieve a power of 
82%, it was calculated that a sample of 37 patients per 
intervention type would be needed. This is assuming a 5% alpha 
error level with a 25% response difference between 
intervention types. 
 
Figure 1. Questionnaire for risk evaluation and potential screening adopted from Bang, et al.6 
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Results 
Table 1: Baseline Characteristics 
Variable TE MI Overall 
N 15 15 30 
Mean age, years 62.6 59.1 60.8 
Female, n (%) 11 (73) 10 (67) 21 (70) 
Anemia 0 (0) 3 (20) 3 (10) 
Hypertension, n (%) 13 (87) 15 (100) 28 (93) 
Clinical ASCVD, n (%) 2 (13) 2 (13) 4 (13) 
Heart Failure, n (%) 1 (7) 3 (20) 4 (13) 
Circulation Disease, n (%)  0 (0) 1 (7) 1 (3) 
Proteinuria, n (%) 0 (0) 0 (0) 0 (0) 
Risk Score, avg 5.5 5.7  5.6 
Currently prescribed an ACE-I/ARB, n (%) 11 (73) 13 (87) 24 (80) 
 
Table 2: Primary and Secondary Outcomes 
Outcome TE MI Overall P-value 
Urinary albumin screening, n/total n (%) 13/15 (87) 15/15 (100) 28/30 (93) 0.4828 
ACE-I/ARB initiation, n/total n (%) 2/2 (100) 1/2 (50) 3/4 (75) 1.000 
Proteinuria, n/total n of screened patients (%) 7/13 (54) 8/15 (53) 15/28 (54) -  
 
From October 2018 to February 2019, a total of 30 patients at 
high risk for CKD were randomized to one of four groups to 
receive either one or two face-to-face education sessions from 
a pharmacist or student pharmacist using either MI or TE 
methods. Given that all patients in groups 2 or 4 accepted the 
screening after the first MI or TE session and therefore, did not 
require a second session, analysis was done for the first session 
only.  
The self-reported characteristics of the patients at baseline 
based on the SCORED tool were well-balanced among study 
groups (Table 1). The mean age among all patients was 60.8 
years, and 70% of the patients were women. The average risk 
score among all patients was 5.6. Age, female sex, and 
concomitant hypertension were the most common risk factors 
resulting in a score of 4 or greater on the SCORED tool. 
Concomitant hypertension was present in 13 of patients in the 
TE group, 11 of which were prescribed an ACE-I or ARB prior to 
the study. All patients in the MI group had a diagnosis of 
hypertension, 13 of which were prescribed an ACE-I or ARB 
prior to randomization. Adherence to the previously prescribed 
ACE-I or ARB was found in 85% of patients in MI group and 91% 
of patients in TE group.  
There was no significant difference in the rate of urinary 
albumin screening (87% in TE vs. 100% in MI, P = 0.4828) 
between education groups (Table 2). Among the patients 
screened, 15 (54%) of patient were found to have proteinuria.  
Education method also did not have a significant impact on the 
rate of ACE-I or ARB initiation (2 of 2 patients in TE and 1 of 2 
patients in MI, P = 1.000) in patients found to have proteinuria 
that were not currently prescribed an ACE-I or ARB (Table 2).    
Of the three patients that accepted ACE-I or ARB initiation, two 
patients were found to be non-adherent to the newly 
prescribed medication.  
Discussion 
The preceding results suggest that pharmacist-delivered 
microalbuminuria screening results in clinically meaningful 
proteinuria identification in diabetic patients of low 
socioeconomic status at high-risk for CKD.  In our study, 54% of 
patients screened were positive for albuminuria, despite no 
known history of proteinuria, which is substantially higher than 
the projected 20% risk of CKD with a “high-risk” score of 4 or 
greater per Bang et al.6 Vart et al. suggests that patients of low 
socioeconomic status are at increased risk of CKD complicated 
by cardiovascular events and significant decline in renal 
function compared to patients with traditional risk factors 
alone, which may account for the relatively high proteinuria 
rates in our patient population.13 In traditional patient 
populations, population-based screening for albuminuria may 
result in fewer cardiovascular events, cardiovascular deaths, 
and dialysis cases in a cost-effective manner.14 The intervention 
used in this study represents a possible strategy to increase 
screening rates in all patient populations, as it required a 
relatively low investment by the pharmacist in terms of time 
and cost of the urine test strips. Each intervention took less 
than five minutes per patient and the urine test strips were 
approximately $2 each. This efficiency in terms of cost and time 
is particularly important in the indigent care setting where 
resources are limited, but may also be used for screenings in 
other outpatient settings.  
Similar to the results seen in Chang et al., our study emphasizes 
that pharmacist intervention may result in increased urinary 
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albumin screening rates in patients previously unscreened.15 
The results of this study indicate that MI had no impact on rates 
of urinary screening or ACE-I/ARB initiation compared to TE 
methods. Therefore, while pharmacist intervention may 
increase compliance with routine screening recommendations, 
it seems that the manner in which the screening services are 
offered has no significant impact on patient willingness to 
undergo screenings.  
Although a majority of patients agreed to urinary screening, 
non-adherence to newly prescribed ACE-I/ARB therapy in 
response to proteinuria remained high. The reason for non-
adherence is not known, but could be due to low patient health 
literacy and/or transportation difficulties, which are common 
barriers to care in the indigent setting. Although there was no 
significant difference between MI and TE in regards to 
acceptance of screening, MI may still have a role in improving 
medication compliance. 
Although the pragmatic study design indicates feasibility of the 
intervention in the primary care setting, this study had some 
important limitations. Because of the small sample size, power 
was not met, resulting in a possible type II error.  Furthermore, 
urinary albumin excretion may be elevated in certain conditions 
(e.g. infection, fever, marked hyperglycemia/hypertension), 
and current guidelines recommend two of three abnormal 
measurements over several months to confirm a diagnosis of 
albuminuria.3 Given the time and resource constraints of our 
practice site, this was not done, and the accuracy of proteinuria 
found in these high-risk patients may be questionable. In 
patients with suboptimal adherence and follow-up, such as 
those in indigent care settings, providers be hesitant to initiate 
ACE-I/ARB therapy due to safety concerns. In our patient 
population, all patients started on an ACE-I/ARB as a part of the 
study had follow-up labs done within 4 to 6 weeks after therapy 
initiation.  
Patient care at the CHC relies heavily on the involvement of 
student pharmacists, which may have affected data collection 
and the consistency of the intervention delivered. While the 
pharmacists that delivered the intervention were formally 
trained in MI, the student pharmacists were not. In an attempt 
to reduce the impact of this on the results, a topic discussion on 
MI was done with all student pharmacists, and a protocol and 
scripts were developed to standardize the education 
interventions. Given all of the patients in the MI group accepted 
the screening after the first session, differences in MI training 
likely did not contribute to the lack of statistical significance 
observed.  
This study was done in an uninsured, low-income patient 
population, and the intervention was done at no cost to the 
patient, possibly increasing patient participation. Acceptance of 
microalbuminuria screening may be lower in patients that must 
pay for screening in an alternative outpatient setting. 
Furthermore, because lisinopril and losartan are on the free or 
low-cost lists at a supermarket chain in Florida, a majority of our 
low-income population were prescribed an ACE-I/ARB prior to 
randomization. In other patient populations, fewer patients 
without previously identified proteinuria, particularly those 
with concomitant hypertension that are self-identified black, 
may have lower rates of current ACE-I/ARB use. Therefore, a 
greater impact on ACE-I/ARB initiation may be found in those 
patients. Finally, because the urine test strips were read 
visually, differences in color perception may have 
overestimated the level of proteinuria. However, this likely did 
not have had a profound impact on patient outcomes given the 
high rates of concomitant hypertension and ACE-I/ARB use in 
our patient population prior to randomization. 
In conclusion, while it appears that MI does not impact patient 
acceptance rates of microalbuminuria screening and ACE-I/ARB 
initiation, this study demonstrates the feasibility of pharmacist-
delivered microalbuminuria screening in patients at high-risk 
for CKD in the outpatient setting. Use of the SCORED tool and 
urine albumin test strips resulted in the identification of 
proteinuria in 54% of screened patients that had not been 
previously diagnosed with CKD. In practice, this may be a cost-
effective method for increasing outpatient microalbuminuria 
screening in high-risk patients. Future studies should measure 
the effect of these educational methods on factors affecting 
CKD progression, such as continued medication adherence and 
limitation of protein intake, and assess the impact of 
pharmacist involvement on other clinical outcomes, including 
glycemic and blood pressure control, drug optimization to 
decrease albuminuria, and medication compliance. 
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Appendix A 
Typical Education Session   
1. If previously identified as ‘high-risk’, inform patient and ask permission to discuss CKD screening. 
2. Provide patient education using the following information: 
a. Because you have diabetes and/or hypertension, you have a higher risk of kidney damage. 
b. Most people do not know that they have damage to their kidneys until it is too late, so it is important to get 
screened, so you can prevent the damage from getting worse. 
c. One of the ways we can tell if you have kidney damage is to test your urine to see if it has protein in it. 
d. If there is protein found in your urine, there is a medication we can start that can help prevent it from getting 
worse. 
e. At the clinic, we provide this testing free. Would you be interested in getting it done today?  
 
Motivational Interviewing Session 
1. Ask permission to explore CKD screening. 
2. Provide patient education using the following motivational interviewing technique: 
a. Ask patient what they know about kidney disease and diabetes. 
b. Use reflective listening 
c. Summarize 
d. Provide-Elicit-Provide: Ask if it would be okay to share some additional information about screening and ways to 
prevent or reduce the progression of CKD with them? If they respond “yes”, provide information and then make 
sure to elicit feedback after providing. If they say “no”, hold off.  
i. Because you have diabetes and/or hypertension, you have a higher risk of damaging your kidneys. 
ii. Most people do not know that they have damage to their kidneys until it is too late, so it is important to 
get screened, so you can prevent the damage from getting worse. 
iii. One of the ways we can tell if you have kidney damage is to test your urine to see if it has protein in it. 
iv. If there is protein found in your urine, there is a medication we can start that can help prevent it from 
getting worse. 
e. Assess motivation, confidence, and readiness to get screened by asking, “We provide the screening test free of 
charge here at the clinic. How would you feel about getting screened today?” 
f. Explore ambivalence. 
i. Ask what are some reasons you think you may want to be screened? 
ii. Ask what are some reasons you think you may NOT want to be screened? 
g. Ask: What would you like to do next? 
h. Make a plan with patient for the future (i.e. provide urine sample today, at later date, etc.) 
 
 
